A 64-year-old man with severe granulomatosis with polyangiitis (GPA) saw his condition improve with the use of a triple combination of standard cyclophosphamide and glucocorticoids along with the experimental therapy telitacicept, according to a case report from China. RemeGen’s telitacicept is approved in China under the brand name…
The severity of anemia, or low levels of oxygen-carrying hemoglobin, is significantly associated with certain kidney lesions in people with ANCA-associated vasculitis (AAV) and kidney involvement, a study showed. These findings “reflect an additional aspect of anemia pathophysiology [disease mechanisms] in ANCA-associated renal vasculitis,” the researchers wrote. The study,…
Treatment with rituximab has a similar efficacy to cyclophosphamide — both of them standard immunosuppressive therapies — in reducing short-time mortality in adults with life-threatening ANCA-associated vasculitis (AAV), a study in Japan found. Moreover, rituximab was associated with a significantly lower risk of fungal infections relative to cyclophosphamide. However,…
Intravenous immunoglobulin (IVIG) therapy appears to be an effective and relatively safe option for people with ANCA-associated vasculitis (AAV), according to real-life study of its use in Spain. All of its 28 AAV patients were resistant to conventional treatments and/or had — or were suspected of having — an…
Among people with ANCA-associated vasculitis (AAV), those with central diabetes insipidus are more frequently diagnosed with granulomatosis with polyangiitis (GPA), a type of AAV, according to a study in China. Central diabetes insipidus, or CDI, is a rare disease characterized by excessive thirst and excessive urine. Patients with…
Researchers in Korea have identified a new index that can predict all-cause mortality in non-obese people with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The index accounts for blood levels of fatty molecules called triglycerides and blood sugar, as well as body mass index (BMI, a ratio of height and…
Daratumumab helped in the remission of severe lung and skin symptoms in a young man with granulomatosis with polyangiitis (GPA), a type of ANCA–associated vasculitis (AAV), scientists in Germany report. An immunotherapy approved to treat multiple myeloma (sold as Darzalex), daratumumab was added after the patient failed to respond…
Maintenance therapy with immunosuppressive agents such as rituximab and azathioprine do not increase the frequency of serious infections beyond what’s expected in people with ANCA-associated vasculitis (AAV), according to a new review study. Regardless of the medication used, fatal infections were uncommon during the maintenance therapy period, data…
Tavneos (avacopan) was generally safe and well tolerated in adults with severe ANCA-associated vasculitis treated under a global early access program (EAP) before the therapy’s approval, a study showed. EAPs make investigational therapies available outside clinical trials to people with serious or life-threatening conditions who have few or no…
A gene variant linked to increased production of proteinase-3 (PR3) — one of the targets of disease-causing antibodies in ANCA-associated vasculitis (AAV) — is more common among patients with anti-PR3 antibodies than those with antibodies against the myeloperoxidase (MPO) protein, a study showed. The higher blood PR3 levels with this…
Get regular updates to your inbox.